Journals / Southern Clinics of Istanbul Eurasia / 2021 / Cilt: 32 - Sayı: 1

The Impact of Graves’ Ophthalmopathy On Anterior and Posterior Ocular Structures: Ocular Imaging Based Study

Pages
75–79
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These parameters might be potential adjuncts in the evaluation of GO patients and preventing ocular serious complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of our study was to evaluate the anterior and posterior ocular parameters in patients with Graves’ ophthalmopathy (GO) compared to control.
📊
Key Findings & Data:Methods: Sixty-eight patients with GO and 40 healthy controls were included in the study.
💡
Conclusion & Impact:These parameters might be potential adjuncts in the evaluation of GO patients and preventing ocular serious complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: The aim of our study was to evaluate the anterior and posterior ocular parameters in patients with Graves’ ophthalmopathy (GO) compared to control. Methods: Sixty-eight patients with GO and 40 healthy controls were included in the study. The patients with GO were divided into two groups according to their clinical activity score (CAS). Patients with ≥3/7 CAS points were entitled as active GO and CAS points less than 3/7 were entitled as inactive GO. Spherical refractive error (SRE), astigmatic refractive error (ARE), central corneal thickness, intraocular pressure, and axial length (AL) were recorded. The subfoveal choroidal thickness (SFCT) and global and sectorial peripapillary retinal nerve fiber layer thickness (pRNFLT) were measured by spectral domain- optical coherence tomography. Results: The patients with active GO had significantly higher myopic SRE and ARE compared to patients with inactive GO and healthy controls (p=0.040 and 0.030, respectively). The mean AL was statistically significant taller in both GO groups than control (p=0.048) but there were no significant differences in AL between the patients with active GO and inactive GO. Patients with active GO and inactive GO had significantly higher SFCT than controls (p≤0.001). Furthermore, patients with active GO had significantly thinner global pRNFLT, superior pRNFLT, inferior pRNFLT, and temporal pRNFLT than patients with inactive GO and active GO. The patients with inactive GO had only thinner inferior pRNFLT compared to healthy controls. Conclusion: The patients with GO had significant alterations in refractive status, SFCT, and pRNFLT, especially patients with active GO. These parameters might be potential adjuncts in the evaluation of GO patients and preventing ocular serious complications.

🔖

Cite This Article

KANAR, H. S. S., OKLAR, M., PENBE, A., ARSAN, A., ŞİMŞEK, E. E. (2021). The Impact of Graves’ Ophthalmopathy On Anterior and Posterior Ocular Structures: Ocular Imaging Based Study. Southern Clinics of Istanbul Eurasia, Cilt: 32 - Sayı: 1, 75–79. https://ajindex.com/articles/313954

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Wiersinga WM, Bartalena L. Epidemiology and Prevention of Graves’ Ophthalmopathy. Thyroid 2002;12:855–60
  2. Hwang S, Byun JW, Yoon JS, Lee EJ. Inhibitory Effects of α-Lipoic Acid on Oxidative Stress-Induced Adipogenesis in Orbital Fibroblasts From Patients With Graves Ophthalmopathy. Medicine (Baltimore) 2016;95:e2497
  3. Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010;362:726–38
  4. McLachlan SM, Prummel MF, Rapoport B. Cell-mediated or humoral immunity in Graves’ ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue. J Clin Endocrinol Metab 1994;78:1070–4
  5. Sezer T, Altınışık M, Koytak İA, Özdemir MH. The Choroid and Optical Coherence Tomography. Turk J Ophthalmol 2016;46:30–7
  6. Luigi B, Lelio B, Alison D, Anja E, Pat K-T, Claudio M, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:273–85
  7. Mombaerts I, Vandelanotte S, Koornneef L. Corneal astigmatism in Graves’ ophthalmopathy. Eye 2006;20:440–6
  8. Jankauskiene J, Jakstaite V, Smalinskas V. Changes of vision and refraction in patients with thyroid pathology. Medicina (Kaunas) 2009;45:378–81
  9. Jankauskiene J, Jarusaitiene D. Assessment of visual acuity, refraction changes, and proptosis in different ages of patients with thyroid diseases. Int J Endocrinol 2012;2012:643275
  10. Kim SA, Jung SK, Paik JS, Yang S-W. Effect of orbital decompression on corneal topography in patients with thyroid ophthalmopathy. PLoS ONE 2015;10:e0133612
  11. Kim WS, Chun YS, Cho BY, Lee JK. Biometric and refractive changes after orbital decompression in Korean patients with thyroid-associated orbitopathy. Eye 2016;30:400–5
  12. Kurioka Y, Inaba M, Kawagishi T, Emoto M, Kumeda Y, Inoue Y, et al. Increased retinal blood flow in patients with Graves’ disease: influence of thyroid function and ophthalmopathy. Eur J Endocrinol 2001;144:99−107
  13. Walasik-Szemplińska D, Pauk-Domańska M, Sanocka U, Sudoł- Szopińska I. Doppler imaging of orbital vessels in the assessment of the activity and severity of thyroid-associated orbitopathy. J Ultrason 2015;15:388–97
  14. Mrejen S, Spaide RF. Optical coherence tomography: Imaging of the choroid and beyond. Surv Ophthalmol 2013;58:387–429
  15. Özkan B, Koçer ÇA, Altintaş Ö, Karabaş L, Acar AZ, Yüksel N. Choroidal changes observed with enhanced depth imaging optical coherence tomography in patients with mild Graves orbitopathy. Eye 2016;30:917–24. 16.